Medicare Enrolled
Dr. Naveed Aslam, MD
Medical Oncology · Troy, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Aslam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Aslam?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Aslam
Dr. Naveed Aslam is a medical oncology specialist in Troy, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Aslam performed 4,394 Medicare services across 568 unique beneficiaries.
Between the years covered by Open Payments, Dr. Aslam received a total of $30,182 from 96 pharmaceutical and/or device companies across 687 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Aslam is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 29% volume in MI
$30,182 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,394
Medicare services
Top 29% in MI for medical oncology
568
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~231 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 2,760 | $18 | $31 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
334 | $90 | $162 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
315 | $8 | $11 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
306 | $0 | $2 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
175 | $129 | $213 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
164 | $6 | $88 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
130 | $10 | $44 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
84 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
59 | $49 | $165 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
36 | $30 | $93 |
| New patient office visit, complex (60-74 min) | 31 | $178 | $299 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
79.2% medium
19.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$30,182
Total received (2018-2024)
Avg $4,312/year across 7 years
Top 13% in MI for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
96
Companies
687
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$15,517 (51.4%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,443 (41.2%)
Other
Charitable contributions, space rental, and other categories
$1,583 (5.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$639 (2.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,305
2023
$2,696
2022
$15,395
2021
$1,409
2020
$1,216
2019
$2,049
2018
$2,113
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$2,520
Novartis Pharmaceuticals Corporation
$851
Janssen Biotech, Inc.
$208
AstraZeneca Pharmaceuticals LP
$194
Tempus AI, Inc
$166
Astellas Pharma US Inc
$123
Genentech USA, Inc.
$116
Daiichi Sankyo Inc.
$97
Eisai Inc.
$64
PFIZER INC.
$60
Merck Sharp & Dohme LLC
$53
E.R. Squibb & Sons, L.L.C.
$53
Stemline Therapeutics Inc.
$50
ABBVIE INC.
$43
JAZZ PHARMACEUTICALS INC.
$43
SOBI, INC
$42
Gilead Sciences, Inc.
$41
Mirati Therapeutics, Inc.
$41
Rigel Pharmaceuticals, Inc.
$40
Incyte Corporation
$39
GlaxoSmithKline, LLC.
$38
SERVIER PHARMACEUTICALS LLC
$31
Celgene Corporation
$30
ARRAY BIOPHARMA INC
$30
Karyopharm Therapeutics Inc.
$28
TAIHO ONCOLOGY, INC.
$28
Bayer Healthcare Pharmaceuticals Inc.
$28
Lilly USA, LLC
$26
Pharmacosmos Therapeutics Inc.
$25
EMD Serono, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$22
TerSera Therapeutics LLC
$20
Ipsen Biopharmaceuticals, Inc
$19
Octapharma USA, Inc.
$18
Aveo Pharmaceuticals, Inc.
$18
BeiGene USA, Inc.
$17
Exelixis Inc.
$17
RECORDATI_RARE_DISEASES_INC.
$16
Verity Pharmaceuticals Inc.
$16
Deciphera Pharmaceuticals Inc.
$16
Top 3 companies account for 67.5% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$13,262
GENZYME CORPORATION
$2,814
Novartis Pharmaceuticals Corporation
$1,806
AstraZeneca Pharmaceuticals LP
$1,280
Genentech USA, Inc.
$1,143
Amgen Inc.
$787
Lilly USA, LLC
$534
Janssen Biotech, Inc.
$527
Celgene Corporation
$512
Astellas Pharma US Inc
$459
PFIZER INC.
$427
E.R. Squibb & Sons, L.L.C.
$330
Seagen Inc.
$325
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Gilead Sciences, Inc.
$298
Eisai Inc.
$268
Merck Sharp & Dohme Corporation
$261
Caldera Medical, Inc
$254
Puma Biotechnology, Inc.
$246
Stemline Therapeutics Inc.
$210
Tempus AI, Inc
$166
TerSera Therapeutics LLC
$165
GlaxoSmithKline, LLC.
$161
Merck Sharp & Dohme LLC
$151
Pharmacyclics LLC, An AbbVie Company
$150
Incyte Corporation
$143
BeiGene USA, Inc.
$121
SOBI, INC
$119
Takeda Pharmaceuticals U.S.A., Inc.
$117
Exelixis Inc.
$117
Rigel Pharmaceuticals, Inc.
$117
ARRAY BIOPHARMA INC
$110
EISAI INC.
$109
Pharmacosmos Therapeutics Inc.
$103
JAZZ PHARMACEUTICALS INC.
$92
Clovis Oncology, Inc.
$83
Boehringer Ingelheim Pharmaceuticals, Inc.
$78
TAIHO ONCOLOGY, INC.
$77
Karyopharm Therapeutics Inc.
$75
Mirati Therapeutics, Inc.
$72
ABBVIE INC.
$71
Kite Pharma, Inc.
$69
PharmaEssentia USA Corporation
$66
SERVIER PHARMACEUTICALS LLC
$65
Alexion Pharmaceuticals, Inc.
$62
Foundation Medicine, Inc.
$62
Taiho Oncology, Inc.
$59
PUMA BIOTECHNOLOGY, INC.
$57
EMD Serono, Inc.
$53
Dova Pharmaceuticals
$52
Medtronic, Inc.
$51
Octapharma USA, Inc.
$49
MACROGENICS, INC.
$48
G1 Therapeutics, Inc.
$45
TESARO, Inc.
$45
Bayer HealthCare Pharmaceuticals Inc.
$42
Spectrum Pharmaceuticals Inc.
$40
ACCORD HEALTHCARE, INC.
$40
Novo Nordisk Inc
$40
Blueprint Medicines Corporation
$40
Pharmacyclics LLC, an AbbVie Company
$39
Endomagnetics Ltd
$38
ImmunoGen, Inc.
$37
Kyowa Kirin, Inc.
$37
Teva Pharmaceuticals USA, Inc.
$35
Bayer Healthcare Pharmaceuticals Inc.
$28
Agios Pharmaceuticals, Inc.
$26
CTI BioPharma Corp.
$25
Acrotech Biopharma Inc.
$24
AMAG Pharmaceuticals, Inc.
$23
Organon LLC
$23
AbbVie Inc.
$22
Genmab U.S., Inc.
$22
Myriad Genetic Laboratories, Inc.
$21
Coherus Biosciences Inc.
$21
Alnylam Pharmaceuticals Inc.
$20
MorphoSys, US Inc.
$19
Ipsen Biopharmaceuticals, Inc
$19
Epizyme, Inc.,
$19
AbbVie, Inc.
$19
Aveo Pharmaceuticals, Inc.
$18
Partner Therapeutics, Inc.
$18
Servier Pharmaceuticals LLC
$18
Array BioPharma Inc.
$17
CSL Behring
$16
RECORDATI_RARE_DISEASES_INC.
$16
Verity Pharmaceuticals Inc.
$16
Janssen Pharmaceuticals, Inc
$16
Deciphera Pharmaceuticals Inc.
$16
Cardinal Health 108 LLC
$16
AVEO Pharmaceuticals, Inc.
$15
Aurobindo Pharma USA, Inc.
$14
Sobi, Inc
$14
MEDIVATION FIELD SOLUTIONS LLC
$12
Acrotech Biopharma LLC
$12
Fortovia Therapeutics, Inc.
$7
Top 3 companies account for 59.2% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ALIMTA · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · BALVERSA · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CAMCEVI · CARVYKTI · CHANTIX · COSELA · CRESEMBA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Desara · Doptelet · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · EXKIVITY · Elahere · Enhertu · Epkinly · Esperoct · FASLODEX · FERAHEME · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · GAZYVA · GILOTRIF · GIVLAARI · HEMADY · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIGASURE · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MARGENZA · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · MYRISK · Magseed · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · NovoSeven · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · RYLAZE · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SOLIRIS · SPRYCEL · SUTENT · SYLVANT · Stivarga · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trelstar · Trodelvy · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Vanflyta · Vectibix · Venclexta · Vonjo · Voranigo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (51%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Medical oncologists within 10 mi
33
Per 100K population
2.6
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Aslam is a mixed practice specialist, with above-average Medicare volume (top 29% in MI), with consulting-driven industry engagement in the top 13% of MI peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Aslam experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Aslam performed 2,760 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Aslam receive payments from pharmaceutical companies?
Yes. Dr. Aslam received a total of $30,182 from 96 companies across 687 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Aslam's costs compare to other medical oncologists in Troy?
Dr. Aslam's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Aslam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Troy
Browse medical oncologists in Troy ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MI
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MI
Which MI medical oncologists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology